OPTIRAY 320 Rx
Generic Name and Formulations:
Ioversol 678mg/mL; soln for intra-arterial or intravenous inj; contains organically bound iodine 320mg per mL.
Indications for OPTIRAY 320:
Adults: Cerebral, peripheral, visceral, renal and coronary arteriography. Aortography, left ventriculography. Computed tomography (CT) imaging of the head and body, venography, and intravenous (IV) excretory urography. Children: Angiocardiography. CT imaging of the head and body and IV excretory urography.
Individualize. Cerebral arteriography (carotid or vertebral arteries): 2–12mL; (aortic arch inj [four vessel study]): 20–50mL; both: may repeat as necessary; max 200mL. Peripheral arteriography (aortic-iliac runoff): 60mL (range 20–90mL); (common iliac, femoral): 40mL (range 10–50mL); (subclavian, brachial): 20mL (range 15–30mL); all: max 250mL. Visceral arteriography, renal arteriography, aortography (aorta): 45mL (range 10–80mL); (celiac): 45mL (range 12–60mL); (superior mesenteric): 45mL (range 15–60mL); (renal or inferior mesenteric): 9mL (range 6–15mL); all: max 250mL. Coronary arteriography and left ventriculography (left coronary): 8mL (range 2–10mL); (right coronary): 6mL (range 1–10mL); (left ventricle): 40mL (range 30–50mL); all: max 250mL. Venography: 50–100mL per extremity; max 250mL. CT (head): 50–150mL by infusion; (body): may give as 25–75mL bolus inj or 50–150mL by infusion, or combination of both. IV urography (usual dose): 50–75mL; (high dose): 1.5–2mL/kg; max 150mL.
Angiocardiography: 1.25mL/kg (range 1–1.5mL/kg); max 5mL/kg up to max 250mL. CT (head and body): 1.5–2mL/kg (range 1–3mL/kg). IV urography: 1–1.5mL/kg (range 0.5–3mL/kg); max 3mL/kg.
Not for intrathecal use.
Not for intrathecal use; may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. History of previous reactions to a contrast agent and known allergies (eg, bronchial asthma, drug, or food) and other hypersensitivities; monitor. Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Monitor for severe cardiovascular reactions. Risk of serious thromboembolic events (eg, MI, stroke) during angiographic procedures. Avoid angiography with homocystinuria. CHF. Dehydration. Diabetes. Advanced vascular disease. Multiple myeloma or other paraproteinemia. Hyperthyroidism. Autonomous thyroid nodule. Pheochromocytoma or catecholamine-secreting paraganglioma: monitor closely. Homozygous sickle cell disease. History of severe cutaneous adverse reactions (SCAR); avoid. Hepatic or renal impairment. Use lowest effective dose. Maintain adequate hydration. Avoid extravasation. Elderly. Pregnancy. Nursing mothers: consider interrupting, pumping, and discarding breast milk for 8hrs after Optiray.
Radiopaque contrast agent.
Increased risk of metformin-induced lactic acidosis; discontinue metformin at the time of, or prior to, Optiray in high risk patients (see full labeling). May antagonize radioactive iodine for thyroid carcinoma for up to 6–8wks. Defer in patients with hepatic impairment who recently received oral cholecystographic contrast agents. Caution with concomitant diuretics, nephrotoxic agents. Avoid laxatives, diuretics prior to administration. Protein-bound iodine or radioactive iodine uptake study results may not accurately reflect thyroid function for up to 16 days.
Nausea; hypersensitivity reactions, acute kidney injury, cardiovascular reactions, SCAR (eg, SJS/TEN, DRESS). Also in children: fever.
OPTIRAY 240: Bottles (50mL)—25, 100mL, 200mL—12, Syringes (125mL)—20; OPTIRAY 300: Bottles (50mL)—25, 100mL, 150mL, 200mL—12, Syringes (50mL, 100mL)—20, RFID-Tagged syringes (100mL)—20; OPTIRAY 320: Vials (20mL, 30mL)—25, Bottles (50mL)—25, 100mL, 150mL, 200mL—12, Syringes (50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (75mL, 100mL, 125mL)—20; OPTIRAY 350: Bottles (50mL)—25, 100mL, 150mL, 200mL—12, Syringes (50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (50mL, 100mL, 125mL)—20
Clinical Pain Advisor Articles
- Opioids: Clinician Concern and Prescribing Practices
- Quantity of Opioids Prescribed Linked to Higher Patient-Reported Consumption
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Ensuring Safety During Long-Term Opioid Therapy
- Drug Overdose Mortality Rates Rising in the United States
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Tips Provided for Budgeting in Medical Residency
- Give Thanks: The Role of Gratitude in Combating Burnout
- Persistent Back Pain Linked to Earlier Mortality in Older Women
- Cannabinoids May Be Effective on Experimental Pain Threshold and Tolerance, Not Intensity
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain